Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer

The incidence of colorectal cancer (CRC) has increased. CRC is the third most common cancer and the fourth most common cause of cancer-related deaths in Korea. Palliative chemotherapy can be used to shrink tumors and ease symptoms caused by the cancer when cure is not possible. It is important to id...

Descripción completa

Detalles Bibliográficos
Autores principales: Baek, Sun Kyung, Lee, Kyu Taek, Bae, Sang Byung, Lee, Sang-Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823574/
https://www.ncbi.nlm.nih.gov/pubmed/31346151
http://dx.doi.org/10.3904/kjim.2019.071
_version_ 1783464561345560576
author Baek, Sun Kyung
Lee, Kyu Taek
Bae, Sang Byung
Lee, Sang-Cheol
author_facet Baek, Sun Kyung
Lee, Kyu Taek
Bae, Sang Byung
Lee, Sang-Cheol
author_sort Baek, Sun Kyung
collection PubMed
description The incidence of colorectal cancer (CRC) has increased. CRC is the third most common cancer and the fourth most common cause of cancer-related deaths in Korea. Palliative chemotherapy can be used to shrink tumors and ease symptoms caused by the cancer when cure is not possible. It is important to identify chemotherapeutic agents that can be used to effectively treat metastatic CRC (mCRC) and thus improve the survival and quality of life of patients with mCRC. This review aimed to evaluate the recent developments in palliative chemotherapy for mCRC and the biological or targeted agents used based on genetic alterations.
format Online
Article
Text
id pubmed-6823574
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Korean Association of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-68235742019-11-12 Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer Baek, Sun Kyung Lee, Kyu Taek Bae, Sang Byung Lee, Sang-Cheol Korean J Intern Med Review The incidence of colorectal cancer (CRC) has increased. CRC is the third most common cancer and the fourth most common cause of cancer-related deaths in Korea. Palliative chemotherapy can be used to shrink tumors and ease symptoms caused by the cancer when cure is not possible. It is important to identify chemotherapeutic agents that can be used to effectively treat metastatic CRC (mCRC) and thus improve the survival and quality of life of patients with mCRC. This review aimed to evaluate the recent developments in palliative chemotherapy for mCRC and the biological or targeted agents used based on genetic alterations. The Korean Association of Internal Medicine 2019-11 2019-07-29 /pmc/articles/PMC6823574/ /pubmed/31346151 http://dx.doi.org/10.3904/kjim.2019.071 Text en Copyright © 2019 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Baek, Sun Kyung
Lee, Kyu Taek
Bae, Sang Byung
Lee, Sang-Cheol
Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
title Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
title_full Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
title_fullStr Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
title_full_unstemmed Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
title_short Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
title_sort evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823574/
https://www.ncbi.nlm.nih.gov/pubmed/31346151
http://dx.doi.org/10.3904/kjim.2019.071
work_keys_str_mv AT baeksunkyung evaluatingtherecentdevelopmentsinpalliativechemotherapyformetastaticcolorectalcancer
AT leekyutaek evaluatingtherecentdevelopmentsinpalliativechemotherapyformetastaticcolorectalcancer
AT baesangbyung evaluatingtherecentdevelopmentsinpalliativechemotherapyformetastaticcolorectalcancer
AT leesangcheol evaluatingtherecentdevelopmentsinpalliativechemotherapyformetastaticcolorectalcancer

Ejemplares similares